Lauren B. Ostermann - Concepedia

Author

Lauren B. Ostermann

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

L Ostermann, Lauren B Ostermann, Lauren B. Ostermann, Lauren Ostermann, Lisa Ostermann

Publications

369

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University Hospital of Zurich University of Zurich

About

Lauren B. Ostermann is an author at The University of Texas MD Anderson Cancer Center specializing in cell biology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	127
2	Cell Biology	4	4	127
3	Health Sciences	1	1	31
4	Natural Sciences	1	1	40
5	Biochemistry	1	1	40

Lauren B. Ostermann

Publications

212

Citations

H-Index

Page 1

	Year	Citations
Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia Hiroki Akiyama, Ran Zhao, Lauren B. Ostermann, Leukemia Redox SignalingMitochondrial FunctionBiochemistryNatural SciencesHematology	2023	40
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia Eric Haines, Yuki Nishida, Michael I. Carr, Scientific Reports Mixed-phenotype Acute LeukemiaAcute Leukemia CellsCell DeathPharmacotherapyCancer Biology	2021	32
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia Sean M. Post, Huaxian Ma, Prerna Malaney, Haematologica Axl/mertk Inhibitor Ono-7475ImmunologyCell DeathPharmacotherapyTumor Biology	2021	31
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics Bing Z. Carter, Po Yee Mak, Wenjing Tao, Blood Cancer Journal	2023	29
Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias Yuki Nishida, Jo Ishizawa, Edward Ayoub, Science Advances	2023	27
Epichaperome inhibition targets <i>TP53-</i>mutant AML and AML stem/progenitor cells Bing Z. Carter, Po Yee Mak, Muharrem Müftüoğlu, Blood ImmunologyCell DeathCancer BiologyTumor BiologyMyeloid Neoplasia	2023	24
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models Hong Mu-Mosley, Lauren B. Ostermann, Muharrem Müftüoğlu, Frontiers in Immunology	2022	18
Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2 Bing Z. Carter, Po Yee Mak, Baozhen Ke, Blood	2023	11

Page 1